These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance. Mehtat Ünlü Ş; Özsan H; Sarıoğlu S Turk J Haematol; 2017 Dec; 34(4):282-288. PubMed ID: 28832010 [TBL] [Abstract][Full Text] [Related]
27. Monoclonal Gammopathy of Renal Significance. Leung N; Bridoux F; Nasr SH N Engl J Med; 2021 May; 384(20):1931-1941. PubMed ID: 34010532 [No Abstract] [Full Text] [Related]
28. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy. Manousaridis I; Loeser C; Goerdt S; Hassel JC Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475 [TBL] [Abstract][Full Text] [Related]
29. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Kapoulas S; Raptis V; Papaioannou M Nephrol Ther; 2015 Jun; 11(3):135-43. PubMed ID: 25861714 [TBL] [Abstract][Full Text] [Related]
33. [Recommendations for the management of monoclonal gammopathies in biochemistry]. Oudart JB; Maquart FX; Ramont L Ann Biol Clin (Paris); 2012; 70(3):251-61. PubMed ID: 22565172 [TBL] [Abstract][Full Text] [Related]
34. Monoclonal gammopathy and neuropathy. Ramchandren S; Lewis RA Curr Opin Neurol; 2009 Oct; 22(5):480-5. PubMed ID: 19625962 [TBL] [Abstract][Full Text] [Related]
36. Monoclonal gammopathy with significance: case series and literature review. Schoot TS; van Apeldoorn M; Sinnige HAM; Beutler JJ Neth J Med; 2020 Jul; 78(4):191-195. PubMed ID: 32641558 [TBL] [Abstract][Full Text] [Related]
37. Monoclonal gammopathy of renal significance: clinical manifestation, pathogenic characteristic and treatment. Cao Q; Qi H; Yao L; Liu Q Panminerva Med; 2020 Mar; 62(1):38-53. PubMed ID: 30848114 [TBL] [Abstract][Full Text] [Related]
38. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Le Cann M; Bouhour F; Viala K; Simon L; Tard C; Rossi C; Morel G; Lagrange E; Magy L; Créange A; Michaud M; Franques J; Echaniz-Laguna A; Antoine JC; Baron M; Arnulf B; Puma A; Delmont E; Maisonobe T; Leblond V; Roos-Weil D Blood; 2020 Nov; 136(21):2428-2436. PubMed ID: 32959046 [TBL] [Abstract][Full Text] [Related]
39. C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report. Alonso-Titos J; Perea-Ortega L; Sola E; Torres-Rueda A; León M; Toledo R; Duarte AD; Vazquez T; Martinez-Esteban MD; Bailen A; Ruiz-Esteban P; Hernandez D BMC Nephrol; 2018 Jun; 19(1):129. PubMed ID: 29884135 [TBL] [Abstract][Full Text] [Related]